Comprehensive genomic profiling of brain tumors to provide targeted therapy options and diagnostic certainty for oligodendrogliomas.

被引：0
|
作者：
Albacker, Lee A.
Pavlick, Dean
Ross, Jeffrey S.
Lesser, Glenn Jay
Corona, Robert John
Colman, Howard
Groves, Morris D.
Hsu, Sigmund H.
Chi, Andrew S.
Miller, Vincent A.
Frampton, Garrett Michael
Ramkissoon, Shakti
机构：
[1] Fdn Med Inc, Cambridge, MA USA
[2] SUNY Upstate Med Univ, Syracuse, NY 13210 USA
[3] Wake Forest Baptist Med Ctr, Winston Salem, NC USA
[4] Hunstman Canc Inst, Salt Lake City, UT USA
[5] Texas Oncol, Austin Brain Tumor Ctr, Austin, TX USA
[6] Mischer Neurosci Associates, Houston, TX USA
[7] NYU Langone Med Ctr & Sch Med, New York, NY USA
[8] Fdn Med Inc, Morrisville, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2039
引用
收藏
页数：1
相关论文
共 41 条
  • [41] Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)
    Kraemer, Alwin
    Mileshkin, Linda
    Bochtler, Tilmann
    Pauli, Chantal
    Duran-Pacheco, Gonzalo
    Arslan, Cagatay
    Bigot, Frederic
    Chalabi, Nassera
    Cook, Natalie
    Italiano, Antoine
    Losa, Ferran
    de Menezes, Juliana Janoski
    Michaud, Chantal
    Ozguroglu, Mustafa
    Pazo-Cid, Roberto A.
    Ross, Jeffrey S.
    Shiu, Kai-Keen
    Stahl, Michael
    Thomas, Marlene
    Moch, Holger
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 234 - 235
12345